Journal Watch · British Journal of Pharmacology · 2026
A PTPRO inhibitor Pi mitigates endotoxemia-induced encephalopathy-mediated blood-brain barrier disruption through cytoskeletal regulation.
In vivo, Pi treatment and PTPRO deficiency reduced BBB leakage, with limited effects on inflammatory cytokines.<h4>Conclusion and implications</h4>These findings identify PTPRO as an important regulator of BBB disruption in endotoxemia-associated encephalopathy and support pharmacological targeting of PTPRO as a potential strategy for preserving sepsis-associated BBB injury.
TL;DR
In vivo, Pi treatment and PTPRO deficiency reduced BBB leakage, with limited effects on inflammatory cytokines.<h4>Conclusion and implications</h4>These findings identify PTPRO as an important regulator of BBB disruption in endotoxemia-associated encephalopathy and support pharmacological targeting of PTPRO as a potential strategy for preserving sepsis-associated BBB injury.
Key findings
- Primary endothelial cells from PTPRO-deficient mice were protected.
- Mechanistically, PTPRO regulated cytoskeletal dynamics through the ErbB2-Rho-MLC2 pathway.
- In vivo, Pi treatment and PTPRO deficiency reduced BBB leakage, with limited effects on inflammatory cytokines.<h4>Conclusion and implications</h4>These findings identify PTPRO as an important regulator of BBB disruption in endotoxemia-associated encephalopathy and support pharmacological targeting of PTPRO as a potential strategy for preserving sepsis-associated BBB injury.
What they did
Barrier dysfunction, cytoskeletal remodelling and signalling events were assessed using permeability assays, immunoblotting, immunofluorescence and in vivo BBB leakage analyses.<h4>Key results</h4>LPS increased PTPRO expression in brain tissue from endotoxemic mice and cerebral endothelial cells. Elevated PTPRO promoted F-actin reorganization, stress fibre formation and intercellular gap formation, whereas Pi treatment or PTPRO silencing attenuated these changes. PTPRO overexpression worsened endothelial barrier dysfunction, while Pi reduced thrombin-induced permeability in bEND.3 cells and wild-type primary endothelial cells.
Full abstract (original)
Background: <h4>Background and purpose</h4>Septic encephalopathy (SE) is closely associated with disruption of blood-brain barrier (BBB), resulting in neurological deficits and poor clinical outcomes. Protein tyrosine phosphatase receptor type O (PTPRO) regulates disease states by dephosphorylating membrane-associated proteins and modulating intracellular signalling. Here we have examined the role of PTPRO in regulating BBB permeability and have assessed a PTPRO inhibitor (Pi) in mitigating BBB disruption during endotoxemia-associated encephalopathy.<h4>Experimental approach</h4>Genetic and pharmacological approaches, including PTPRO overexpression, knockdown or deficiency and Pi treatment, were used to evaluate endothelial dysfunction in bEND.3 cells, primary mouse brain microvascular endothelial cells and an LPS-induced murine model of endotoxemia-associated encephalopathy.
What they did: Barrier dysfunction, cytoskeletal remodelling and signalling events were assessed using permeability assays, immunoblotting, immunofluorescence and in vivo BBB leakage analyses.<h4>Key results</h4>LPS increased PTPRO expression in brain tissue from endotoxemic mice and cerebral endothelial cells. Elevated PTPRO promoted F-actin reorganization, stress fibre formation and intercellular gap formation, whereas Pi treatment or PTPRO silencing attenuated these changes. PTPRO overexpression worsened endothelial barrier dysfunction, while Pi reduced thrombin-induced permeability in bEND.3 cells and wild-type primary endothelial cells.
Results & conclusions: Primary endothelial cells from PTPRO-deficient mice were protected. Mechanistically, PTPRO regulated cytoskeletal dynamics through the ErbB2-Rho-MLC2 pathway. In vivo, Pi treatment and PTPRO deficiency reduced BBB leakage, with limited effects on inflammatory cytokines.<h4>Conclusion and implications</h4>These findings identify PTPRO as an important regulator of BBB disruption in endotoxemia-associated encephalopathy and support pharmacological targeting of PTPRO as a potential strategy for preserving sepsis-associated BBB injury.
Abstract © the authors / British Journal of Pharmacology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1111/bph.70682 · PubMed 42885181.
Why it matters for pharma & biotech
- Directly relevant to teams in small-molecule drug discovery — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
- As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
- For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.
Modalities & themes detected: small-molecule drug discovery
Limitations & what to check in the full text
- This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
- The work is preclinical. Results in animal or cell models frequently do not translate directly to human efficacy or safety.
- The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.
Frequently asked questions
What did this British Journal of Pharmacology study find?
In vivo, Pi treatment and PTPRO deficiency reduced BBB leakage, with limited effects on inflammatory cytokines.<h4>Conclusion and implications</h4>These findings identify PTPRO as an important regulator of BBB disruption in endotoxemia-associated encephalopathy and support pharmacological targeting of PTPRO as a potential strategy for preserving sepsis-associated BBB injury.
What type of study is this?
It is a preclinical (animal / model) study, published in British Journal of Pharmacology in 2026. Barrier dysfunction, cytoskeletal remodelling and signalling events were assessed using permeability assays, immunoblotting, immunofluorescence and in vivo BBB leakage analyses.<h4>Key results</h4>LPS increased PTPRO expression in brain tissue from endotoxemic mice and cerebral endothelial cells.
Where can I read the original paper?
The original is at the publisher via DOI 10.1111/bph.70682. PubMed ID: 42885181. BioStudioAI reproduces the abstract for discussion and links to the source.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/a-ptpro-inhibitor-pi-mitigates-endotoxemia-induced-encephalopathy-mediat-h70682/
Reading papers is step one. Analysing the data is the work.
BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.
Open BioStudioAI More guides